NN1731

11/01/2009 - "This suggests that NN1731 holds its promise as a future bypassing agent for haemophilia patients with and without inhibitors."
04/01/2007 - "At the dose tested, NN1731 even shortened CT in haemophilia below the value of healthy males. "
09/01/2009 - "This study shows that NN1731 has a greater efficacy and faster resolution of bleeding in a severe bleeding model in hemophilia A mice compared with any of the other agents tested."
09/01/2007 - "Overall, haemophilia blood samples with or without inhibitors spiked with NN1731 had significantly greater PCF, CEM and shorter FOT values relative to samples spiked with corresponding doses of rFVIIa. "
04/01/2007 - "Altogether, these in vitro studies on WB revealed a favourable haemostatic potential of NN1731 compared with rFVIIa in severe haemophilia A, both in the absence and presence of enhanced fibrinolytic activity."

09/01/2007 - "NN1731 may be a promising haemostatic agent for patients with bleeding disorders. "
09/01/2009 - "This study shows that NN1731 has a greater efficacy and faster resolution of bleeding in a severe bleeding model in hemophilia A mice compared with any of the other agents tested."
12/01/2009 - "After a liver trauma in the pig, i.v. administration of NN1731 reduced the bleeding and increased the survival time. "
09/01/2009 - "Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice."
11/01/2010 - "In summary, rFVIIa and NN1731 significantly and dose-dependently reduced bleeding in extensively hemodiluted rabbits."

01/01/2009 - "The present study evaluated dynamic coagulation profiles, platelet aggregation, and thrombin generation in whole blood (WB) from eight children with thrombocytopenia during chemotherapy, and the haemostatic potential of platelets (+60 x 10(9)/l), recombinant factor VIIa (rFVIIa - NovoSeven), and a potent rFVIIa analogue (NN1731) both at 1 and 4 microg/ml. Dynamic WB coagulation profiles were recorded by thrombelastometry employing activation with tissue factor (TF - Innovin) at low concentrations. "

12/01/2009 - "After a liver trauma in the pig, i.v. administration of NN1731 reduced the bleeding and increased the survival time. "
12/01/2009 - "administration of the coagulation factor VIIa analogue NN1731 on haemorrhage after a liver trauma in the pig. "
12/01/2009 - "Effects of a recombinant FVIIa analogue, NN1731, on blood loss and survival after liver trauma in the pig."

11/01/2009 - "Normalization of maxTG required 500 nm rFVIIa and 25 nm NN1731 or 25-100 nm rFVIIa and 5 nm NN1731 in severe or moderate/mild haemophilia A and haemophilia B, respectively. "